Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial( )

AIMS: The presence of pulmonary hypertension (PH) severely aggravates the clinical course of heart failure with preserved ejection fraction (HFpEF). To date, neither established heart failure therapies nor pulmonary vasodilators proved beneficial. This study investigated the efficacy of chronic trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Dachs, Theresa Marie, Duca, Franz, Rettl, René, Binder-Rodriguez, Christina, Dalos, Daniel, Ligios, Luciana Camuz, Kammerlander, Andreas, Grünig, Ekkehard, Pretsch, Ingrid, Steringer-Mascherbauer, Regina, Ablasser, Klemens, Wargenau, Manfred, Mascherbauer, Julia, Lang, Irene M, Hengstenberg, Christian, Badr-Eslam, Roza, Kastner, Johannes, Bonderman, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492239/
https://www.ncbi.nlm.nih.gov/pubmed/35909264
http://dx.doi.org/10.1093/eurheartj/ehac389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492239/
https://www.ncbi.nlm.nih.gov/pubmed/35909264
http://dx.doi.org/10.1093/eurheartj/ehac389

Ejemplares similares